Kevin O’Reilly
About
In The Last Decade
Kevin O’Reilly
27 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 112
- Physiology 826
- Orthopedics and Sports Medicine 517
- Cell Biology 444
- Molecular Biology 419
- Complementary and alternative medicine 354
Countries citing papers authored by Kevin O’Reilly
This map shows the geographic impact of Kevin O’Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin O’Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin O’Reilly more than expected).
Fields of papers citing papers by Kevin O’Reilly
This network shows the impact of papers produced by Kevin O’Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin O’Reilly. The network helps show where Kevin O’Reilly may publish in the future.
Co-authorship network of co-authors of Kevin O’Reilly
This figure shows the co-authorship network connecting the top 25 collaborators of Kevin O’Reilly. A scholar is included among the top collaborators of Kevin O’Reilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin O’Reilly. Kevin O’Reilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 11 | |
| 3 | 9 | |
| 4 | Anti-CD9 antibody, AR40A746.2.3, inhibits tumor growth in pancreatic and breast cancer models and recognizes CD9 on CD34+CD38- leukemic cancer stem cells. | 2 |
| 5 | AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models | 7 |
| 6 | 9 | |
| 7 | 17 | |
| 8 | 124 | |
| 9 | 61 | |
| 10 | 260 | |
| 11 | 234 | |
| 12 | Strength conditioning in older men: skeletal muscle hypertrophy and improved function breakdown → | 1074 |
| 13 | 120 | |
| 14 | 6 | |
| 15 | 15 | |
| 16 | 0 | |
| 17 | 3 | |
| 18 | 2 | |
| 19 | 5 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.